Clearmind Secures Japanese Patent for 3-MMC-Based Neurological Disorder Treatment
Event summary
- Clearmind's Japanese patent application covers 3-MMC-based treatment for dyskinesia, a neurological movement disorder.
- The patent includes combinations of 3-MMC with Palmitoylethanolamide (PEA), an anti-inflammatory and neuroprotective compound.
- This development is part of Clearmind's ongoing collaboration with NeuroThera Labs Inc.
- Clearmind currently holds 19 patent families, including 32 granted patents.
- The patent publication occurred on October 8, 2026.
The big picture
Clearmind's patent publication in Japan underscores its strategy to build a robust intellectual property portfolio around its neuroplastogen-derived therapeutics. This move aligns with broader industry trends of leveraging psychedelic-derived compounds for treating underserved neurological conditions. The collaboration with NeuroThera Labs further solidifies Clearmind's position in the biopharmaceutical sector, particularly in the development of non-hallucinogenic treatments for conditions like dyskinesia.
What we're watching
- IP Expansion
- How Clearmind's global IP position will strengthen its market advantage in treating neurological disorders.
- Clinical Progress
- The pace at which Clearmind advances its 3-MMC-based treatments through clinical trials.
- Partnership Dynamics
- Whether the collaboration with NeuroThera Labs will yield additional therapeutic breakthroughs.
Related topics
